"With this last patient's treatment visit completed, our team will start the study closeout process, and the Company plans announce topline results in Q3," said Cuong Do, BioVie's President and CEO. "This trial was designed to assess bezisterim's magnitude of therapeutic impact on a series of motor and non-motor endpoints so that we can finalize the design for the Phase 3 registrational trials. We look forward to unblinding the data later this year to understand the molecule's true potential."

The company recently hosted a virtual key opinion leader (KOL) event featuring Suzanne de la Monte, MD, MPH, professor in Pathology and Laboratory Medicine, Neurology, & Neurosurgery at the Warren Alpert Medical School of Brown University, who joined company management to discuss the importance of insulin resistance in disease pathology and bezisterim's mechanism of action in relation to the pathology and progression of neurodegenerative conditions, including Parkinson's disease. The event also discussed the need to address Parkinson's non-motor symptoms, including sleep disorder, anxiety, depression and cognitive slowness.